老年晚期非小细胞肺癌患者临床特点和吉非替尼的临床疗效观察

目的 探讨老年晚期非小细胞肺癌患者的临床特点和应用吉非替尼治疗的临床疗效。方法 选取2009年1月—2013年10月接受治疗的200例老年晚期非小细胞肺癌患者为研究对象,采用随机数字表法将患者平均分成二组,观察组与对照组,每组各100例。对照组患者给予多西紫衫醇治疗,75mg/m2,静滴;观察组实施吉非替尼治疗,250mg/d,口服。总结老年晚期非小细胞肺癌患者的临床特点并比较二组患者的临床疗效。结果 200例老年晚期非小细胞肺癌患者中男女比例近3：1,61%的患者有吸烟史,腺癌和鳞癌患者达174例（87%）。观察组患者与对照组相比较,治疗有效率为（36%vs12%）,控制率为（74%vs 43%）,中位生存时间为（7.3vs 3.9）个月,均明显高于对照组,二组比较差异有统计学意义（P〈0.05）。结论 应用吉非替尼治疗老年晚期非小细胞肺癌可以显著改善患者的临床症状,延长患者的生存期,临床疗效显著,且不良反应轻微,安全性好,是临床治疗老年晚期非小细胞肺癌的有效途径。

THE CLINICAL CHARACTERISTICS OF ELDERLY PATIENTS WITH ADVANCED NON -SMALL CELL LUNG CANCER AND THE RESEARCH OF CLINICAL EFFICACY OF GEFITINIB

Objective To investigate the clinical characteristics of elderly patients with advanced non-small cell lung cancer and the clinical efficacy of gefitinib.Methods Totally200 cases of elderly patients with advanced non-small cell lung cancer patients in author＇s hospital from January 2012 to October 2013 were selected for the study.They were divided into two groups,the experimental group and the control group,each with 100 cases.The control group was treated with docetaxel,and the experimental group was received gefitinib therapy.This article summarized the clinical characteristics of elderly patients with advanced non-small cell lung cancer,and compared the clinical efficacy and adverse reactions between the two groups.Results The male to female ratio of 200 cases elderly patients with advanced non-small cell lung cancer was about 3：1,and 61% of patients had a history of smoking,and 174 cases（87%）had adenocarcinoma and squamous cell carcinoma.The effect rates and control rates of experimental group were25% and 75% respectively,and the median survival time was 7.2 months,which were significantly higher than the control group.There was a significant difference between the two groups（P〈0.05）.Conclusion The clinical efficacy of gefitinib with elderly patients with advanced non-small cell lung cancer is significantly,which can significantly improve the clinical symptoms and prolong survival of patients.It＇s a safety clinical treatment for elderly patients with advanced non-small cell lung cancer.